# EDGAR Filing Document

**Accession Number:** 0001357874
**File Stem:** 0000000000-26-000019
**Filing Date:** 2026-1
**Character Count:** 2272
**Document Hash:** bb442e058cc820f9ba11a1a70cc2cbfa
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-26-000019.hdr.sgml**: 20260331

**ACCESSION NUMBER**: 0000000000-26-000019

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260102

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PRECISION BIOSCIENCES INC
- **CENTRAL INDEX KEY:** 0001357874
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-292478

**BUSINESS ADDRESS:**
- **STREET 1:** 302 EAST PETTIGREW STREET
- **STREET 2:** SUITE A-100
- **CITY:** DURHAM
- **STATE:** NC
- **ZIP:** 27701
- **BUSINESS PHONE:** 919-314-5512

**MAIL ADDRESS:**
- **STREET 1:** 302 EAST PETTIGREW STREET
- **STREET 2:** SUITE A-100
- **CITY:** DURHAM
- **STATE:** NC
- **ZIP:** 27701
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001628280-25-059077

## Text-Extract

```

                                                           January 2, 2026

Michael Amoroso
President and Chief Executive Officer
Precision BioSciences, Inc.
302 East Pettigrew St., Suite A-100
Durham, North Carolina 27701

       Re: Precision BioSciences, Inc.
           Registration Statement on Form S-3
           Filed December 30, 2025
           File No. 333-292478
Dear Michael Amoroso:

       This is to advise you that we have not reviewed and will not review your
registration
statement.

        Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Chris Edwards at 202-551-6761 with any questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:   Nathan Ajiashvili, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._